Approval · Notice of Compliance 37176 · 2026
SERC: Notice of Compliance 37176
Issued March 25, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37176
- Date
- March 25, 2026
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph reformatted to the Master Template.Replacement of a manufacturing site and/or manufacturer involving production of the drug substance. Change in the composition of a dosage form. Change in the drug product manufacturing process. Change in the specification for the drug product
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SERC | Not yet assigned | — |
Medicinal ingredients
- BETAHISTINE HYDROCHLORIDE 16 MG per TAB
- BETAHISTINE HYDROCHLORIDE 24 MG per TAB